Reliance-backed genomics company is pursuing US FDA approval for CancerSpot and aims to cut its price in India to below ₹10,000 over the next two to three years.
The post Strand eyes US, Southeast Asia mkts for blood-based cancer screening test appeared first on Home Page.
